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Abstract 
Background: The debate on the non-medical use of prescription 
medication for the enhancement of cognitive function (e.g., attention, 
memory, concentration, vigilance), accompanied by heated public 
discussions in the media, has spurred the interest of scholars and the 
public. 
Methods: In this paper, we present qualitative data from a focus group 
study with university students, parents, and healthcare providers. We 
identified ethical, social, and legal issues related to the non-medical use of 
methylphenidate for cognitive enhancement (CE) and closely examined 
the positions taken on these issues and their supporting arguments. 
Results: The ethical, social, and legal issues we identified (e.g., 
authenticity, cheating) were similar to those identified in a previous 
discourse analysis of the bioethics literature but indicate the existence of 
moderately and highly contentious issues as well as factors and values 
underlying these issues. The model we generated from these findings 
shows how interplay between values (e.g., effort and honesty) and 
external factors (e.g., regulation and access) may lie at the root of 
contentious ethical issues in CE.  
Conclusions: Our discussion points to an unsuspected complexity in 
understanding values of stakeholders and their unclear relationship to 
academic discourse and professional societies. We propose deliberative 
or other democratic processes as a way to recognize and incorporate the 
complexity of the CE debate.  
 
Keywords: cognitive enhancement, neuroethics, focus groups, 
stakeholder perspectives, professional guidelines, pragmatism 
 
Background 
The debate on the non-medical use of prescription medication for the 
enhancement of cognitive function (e.g., attention, memory, concentration, 
vigilance) has spurred the interest of scholars (Farah et al. 2004; Hall 
2004; Greely et al. 2008; Forlini and Racine 2011) and the public through 
heated discussions in the media (Forlini and Racine 2009b). Several 
specific ethical issues surrounding this phenomenon (often called 
“cognitive enhancement” (CE) by academics) have now been described 
and discussed at length (President's Council on Bioethics 2003; 
Chatterjee 2004; Farah et al. 2004; Hall 2004; Mehlman 2004; Bush 
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2006). Throughout this debate, little consensus exists on the moral 
acceptability or moral praiseworthiness of CE (Racine 2010). It has been 
suggested by some authors that cognitive enhancers “should be viewed in 
the same general category as education, good health habits, and 
information technology – ways that our uniquely innovative species tries to 
improve itself” (Greely et al. 2008, p. 702). Yet others consider that 
“biotechnological enhancement fundamentally alters the essence of what it 
means to be an individual” (Bush 2006, p. 131). These opposing points of 
view have been associated with the broader framework of the “culture 
wars”, which underlies many polarized American bioethics debates like 
stem cell research and end-of-life care (Racine 2010). The entrenched 
opposition that characterizes the perspectives within academic ethics 
creates blind spots, resulting in a lack of attention to underlying values and 
assumptions (Parens 2005) that could have consequences in the 
development of cohesive policy approaches, irrespective of their liberal or 
conservative orientations. 
A second debate concerns whether CE poses novel and salient 
ethical issues of its own and what type of attention and response, if any, 
these issues require. Scholars have voiced  healthy scepticism about the 
novelty of the questions related to CE based on precedent lifestyle use of 
illicit and prescription drugs (Lucke et al. 2010) or exaggerations about the 
effects and prevalence of CE1 (Outram 2010). As such, the nature of the 
debate and response to CE becomes a phenomenon to reflect on in its 
own right. This is important in light of comments that the academic debate 
is overly polarized to the point where advocacy – rather than open scrutiny 
– better describes current scholarship, in bioethics generally and in the 
debate about CE specifically (Callahan 2005; Parens 2005; Racine 2010). 
Exaggerations of the novelty and prevalence of CE, along with a dubious 
use of CE terminology within the academic literature, (Racine and Forlini 
                                                          
1 Estimates of the proportion of university students using stimulants to enhance academic 
performance range from 1.3% to 11% (Wilens et al. 2008; Racine and Forlini 2010; 
Franke et al. 2011).  
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2010) suggest that academia has not necessarily been an impartial and 
reasonably objective participant in the CE debate (Hall and Lucke 2010; 
Lucke et al. 2010; Outram 2010; Forlini and Racine 2011). Moreover, 
assumptions about the effects and prevalence of CE could prevent open-
ended discussion and stifle debate by suggesting that “cognitive 
enhancement” is by nature an “enhancement” (Racine and Forlini 2010) or 
that prevalence creates pressures to hastily condone the moral 
acceptability of CE more generally (Lucke et al 2010). 
 These points of contention within academic debates have 
complicated efforts to map the ethical landscape of CE, while also 
structuring the debate in ways that may create or perpetuate blind spots. 
For example, in policies and guidelines about CE produced by two 
professional societies and a government committee, commonly shared 
assumptions such as (1) the strong need for professional guidance, (2) the 
urgent need for social discussion, (3) estimates of high prevalence and 
widespread demand for enhancers (Outram and Racine 2011) have 
already been cited as motivators for advice on governance on how to 
approach CE in an ethical manner (British Medical Association 2007; 
Larriviere et al. 2009; Commission de l'éthique de la science et de la 
technologie 2009). There is therefore the potential, as we have argued 
elsewhere, for the academic debate focused on the ethics of CE to 
actually perpetuate blind spots with respect to the way that issues are 
identified, discussed, and approached in the public domain in the 
development of policies with little reality check and input from non-
academic perspectives on CE (Racine and Forlini 2010; Forlini and Racine 
2011).  
An emerging body of research has begun to shed some light on 
potential blind spots within academic CE discourse by investigating the 
perspectives of different stakeholders with regard to the non-medical use 
of prescription medication. These data create the possibility of better 
situating the ethics debate within relevant social contexts and redirecting, 
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if needed, the academic ethics debate to address issues that are important 
to stakeholders. So far, stakeholders in these studies consist of university 
students or members of the public (Sabini and Monterosso 2005; Riis, 
Simmons and Goodwin 2008), healthcare professionals (Banjo, Nadler 
and Reiner 2010; Hotze et al. 2011) and combinations of these groups 
(Bergstrom and Lynoe 2008; Forlini and Racine 2011; Forlini and Racine 
In press). These empirical studies employ methodologies, both 
quantitative and qualitative, that allowed the authors to identify attitudes, 
opinions, and reactions to different aspects of CE and CE-related ethical 
issues. Results have honed in on specific issues (e.g., autonomy, fairness, 
authenticity), providing more information on how stakeholders grapple with 
the permissibility of CE. The results of these studies help illuminate the 
real-world context of CE, adding important facets and realities that inform 
and enrich academic debates but can also sometimes radically contradict 
or call into question assumptions made in these debates which may not 
reflect the real-world context of CE. In a striking study, Riis et al. used a 
series of vignette experiments to show that healthy young individuals are 
more reluctant to enhance traits that are perceived to be fundamental 
aspects of their self-identities than those which are believed to be less 
fundamental (Riis, Simmons and Goodwin 2008). However, attitudes 
toward legal access are not shaped by this perspective on self-identity but 
rather by moral concerns (e.g., fairness and authenticity). We have 
previously reported that both liberal and more “conservative” or prudential 
academic bioethics positions on CE may err fundamentally in their 
assumptions about individuals’ levels of freedom to either choose or 
refuse CE; both positions are in radical disconnect with perceived 
pressures and coercion (Forlini and Racine 2009a). In other studies, 
healthcare providers emphasized concerns for the safety and efficacy of 
medications used for CE as well as issues of social justice in terms of 
distribution and potential insurance coverage (Banjo, Nadler and Reiner 
2010; Hotze et al. 2011). These studies show the psychological complexity 
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underlying perspectives regarding the ethics of CE, in contrast to some of 
the more simplistic assumptions made within the polarized academic 
ethics debate as well as in discussion of policy and professional 
associations. This contrast between academic and non-academic 
discourses is suggestive of parallel debates in the multiple approaches to 
the ethics of CE (Forlini and Racine 2011).   
In this paper, we sought to identify the ethical, social, and legal 
issues that are most important to stakeholders and to better understand 
the values at the root of ethical contentions about CE. We present 
qualitative data from a focus group study that we hope will enrich 
comprehension of ethical issues in CE with experiential knowledge and 
perspectives  contribute to a grounded understanding of different 
stakeholder perspectives on CE and the emerging literature on non-
academic stakeholder perspectives on CE.  
The study was inspired by an open-ended research approach 
grounded in pragmatism (Racine 2010) as a pathway to develop 
empirically-based ethical approaches in a context of unclear moral 
intuitions and pervasive academic debate. The data we acquired 
contribute to furthering our understanding of social and psychological 
factors underlying the CE debate while shaping a complex picture of public 
attitudes to CE. We discuss specifically how academic approaches fall 
short of capturing values of importance to stakeholders, most notably 
authenticity. We argue that current policies would benefit from attending to 
the values underlying public perspectives toward CE, although this would 
call for non-conventional approaches to develop policies through open 
deliberation. 
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Methods2 
We focused our study on methylphenidate (MPH). Methylphenidate is a 
prescription stimulant that is used to control the symptoms of Attention 
Deficit/Hyperactivity Disorder (ADHD) and is more commonly known under 
the commercial name Ritalin (Canadian Pharmacists Association 2008). 
This prescription drug is often cited as being used by university students to 
increase academic performance (Teter et al. 2003; Barrett et al. 2005; 
Arria and Wish 2006; Teter et al. 2006; Wilens et al. 2008) in spite of 
unclear evidence about its efficacy (Repantis et al. 2008, 2010, 2010).  
Participants 
Participants consisted of three groups: university students 25 and under, 
parents of university students and healthcare providers (HCP). Each group 
brought a different perspective. The age limit on university students 
reflects data showing that the practice exists among undergraduate 
students (Babcock and Byrne 2000; White, Becker-Blease and Grace-
Bishop 2006). Parents of university students provide a generational 
difference and they are directly connected to university education. 
Healthcare providers work closely with medications to treat disease, 
making their perspective on the repurposing of MPH for CE of interest to 
this study. A HCP was defined as someone having a professional 
responsibility to care for the health of patients (e.g., doctors, nurses, 
pharmacists). No particular expertise with MPH was required.  
Recruitment 
The study and the recruitment strategies were approved by the Research 
Ethics Board (REB) of institutions where the study was conducted. English 
and French recruitment advertisements were posted in common areas of 
                                                          
2 The data presented in this article is part of a larger study of which the methodology and 
other non-overlapping data have been previously published (Forlini and Racine 2009a; 
Forlini and Racine In press). ( 
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two universities and affiliated institutions. Advertisements were also 
featured in various general and student newspapers as well as online 
classified sites. E-mail invitations were sent to major student associations 
and faculty members in healthcare professions. Participants received 
compensation ($50) for their time.  
Focus groups 
Focus groups, as a method, allowed us to gain insight into broader 
stakeholder perspectives as opposed to those of single individual which 
could be gathered in a survey approach. To minimize recruitment bias and 
encourage participation of non-experts, participants remained unexposed 
to the specific subject of the discussion (CE with MPH) until they received 
the documentation package. This package included a print media sample 
of four articles, a consent form, and a short questionnaire. The articles 
were chosen from a systematic print media sampling of prior discourse 
analysis (Racine and Forlini 2010). To maximize the scope of the focus 
group discussion, articles were selected to reflect variability in content 
(e.g., details about how students obtain pills, effects, and testimonials), 
quality of information, overall coverage of ethical issues, length, and 
country of origin (Laurance 2003; Zernike 2005; Morency 2006; Ross 
2006). After reading the articles, participants were asked to fill out an 
anonymous questionnaire collecting demographic data and information 
about prior knowledge of CE with MPH.  
The interview grid for the focus groups was based on the results of 
prior discourse analysis, which identified salient ethical issues in different 
literature, including the print media (Racine and Forlini 2010).  We tested 
the interview grid with three pilot interviews to gauge the appropriateness 
and comprehension of our questions. During the focus groups, participants 
were first invited to comment generally on CE and then express their 
opinions regarding the ethical, social, and legal issues related to CE. They 
were also asked to comment on the potential ethical, legal, social, and 
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healthcare impacts of CE as well as solutions to these issues. Finally, 
participants were asked to give their impression on the media coverage of 
MPH for CE based on the prompt material. The focus groups were 
moderated by one of the authors (ER) to allow spontaneous expression of 
opinions while ensuring coverage of the topics included in the interview 
grid. The other author (CF) assisted the moderator and took field notes. 
Coding 
Each focus group discussion was recorded and transcribed verbatim. The 
transcripts were coded systematically using QSR NVivo 7 software 
(Doncaster, Australia) according to a previously used coding guide that 
identified major themes and issues from lay, bioethics, and public health 
discourses on CE (Forlini and Racine 2009b). This previous coding guide, 
used to analyze academic discourse and print media content, was 
modified and enriched to reflect the novel perspectives of focus group 
participants, especially regarding reactions toward CE and the media 
coverage, through pilot coding by both authors. The full transcripts were 
then systematically coded by one author (CF) and verified by another 
author (ER). Disagreements were settled by discussion and the 
achievement of consensus.  
Figure 6.1 shows the overall methodological approach for coding 
and analysis of the ethical issues discussed during the focus groups. The 
complete coding guide captured many facets of the CE debate that were 
also part of the interview guide and focus group discussions. The first part 
of the coding guide captured stakeholder reactions to CE where they 
proposed definitions and reacted to the frequency and social acceptability 
of CE. The second part dealt with ethical, social, and legal concerns 
related to CE, including safety and efficacy, legality, potential risks and 
benefits, and other issues related to academic performance (e.g., 
authenticity and cheating). The third part explored social (e.g., abuse, 
autonomy, social meaning) and healthcare aspects (e.g., overprescription, 
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commercialization and injustice).  The final part of the coding guide 
recorded perspectives on the media coverage of CE based on the prompt 
materials that were previously provided.  
Within the codes for each of the ethical, social, and legal issues in 
the second and third parts of the guide, participants’ statements were 
further categorized in order to identify participants’ positions on the ethical 
issues (See section 1B of Figure 6.1). If a participant’s statement 
expressed that the issue in question posed an ethical, social, legal 
problem or had a significant impact it was coded as an “affirmation”.  If, on 
the contrary, a participant’s statement denied the existence of a problem 
or its impact, it was coded as a “negation”. Statements that mentioned an 
issue but neither affirmed nor negated a problem, or represented both 
points of view were coded as “neutral”. Likewise, if the statements clearly 
indicated that the speaker was uncertain, the code “neutral” was applied. 
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Figure 6.1: Methodological approach for coding and analysis of ethical, social and legal issues* identified and discussed 
during focus groups. 
  
 
 
 
 
 
 
Focus 
group 
transcripts 
A. Ethical issues 
Abuse 
Authenticity, identity and 
personhood 
Autonomy** 
Cheating 
Commercialization 
Illegality 
Injustice, access and equality 
Overprescription 
Safety and efficacy 
Social meaning 
B. Positions 
Affirmation:  
presence of an 
ethical issue 
Negation:  
absence of an 
ethical issue 
Neutral:  
uncertain of the  
presence of an 
ethical issue or of 
ethical position 
A. Determining contention 
 
Non-contentious:  
Ethical issue is not 
recognized or not 
problematized    
Moderately contentious:  
acknowledgement of an  
ethical issue with  
consensual stances 
Highly contentious:  
acknowledgement of an  
ethical issue with diverse  
stances 
1. Coding – Identify ethical, 
social and legal issues (A) 
and positions taken (B) in 
the focus groups 
**issue not reported in this paper 
 
2. Analysis – Assessing 
level of contention (A) in 
ethical, social and legal 
issues based on overall 
positions taken 
(affirmation, negation, 
neutral) and relationships 
(B) between the ethical 
   
 
B. Model of 
relationships 
between ethical 
issues and  
underlying 
values 
 
* Ethical, social and legal issues are abbreviated as “ethical issues”. 
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In this paper, we report results on the following aspects of the 
debate over the ethical, social, and legal issues3 around the non-medical 
use of MPH for CE: (1) abuse; (2) authenticity, identity and personhood; 
(3) cheating; (4) commercialization; (5) illegality; (6) injustice, access, and 
equality; (7) overprescription; and (8) social meaning. Issues of autonomy 
and potential for coercion to use medications for CE (Forlini and Racine 
2009a) as well as stakeholder views on the safety and efficacy of using 
MPH for CE (Forlini and Racine In press) have been reported elsewhere 
(See Section 1A of Figure 6.1). These data are largely non-overlapping 
but the nature of qualitative data does mean that there are small 
convergences between the general data set reported here and more 
specific pieces of data previously published (Forlini and Racine 2009a; 
Forlini and Racine In press).    
Analysis 
The analysis of coded statements was twofold. First, we examined the 
acknowledgement (or lack of acknowledgement) of a substantial ethical 
question for each issue to determine whether an issue was contentious or 
not. We then examined the positions taken (affirmation, negation and 
neutral) for each coded ethical issue as well as the specific arguments for 
each side to determine the extent of contention. . These specific 
arguments are presented in Table 6.1 as well as Figures 6.2-6.5. Bold 
italic fonts provide the broader reasons underlying the specific positions 
taken on particular ethical issues.  The relative proportion and qualitative 
diversity of the arguments in the affirmation, negation, and neutral 
categories determined the extent (highly or moderately) to which a specific 
ethical issue was contentious or not. An ethical issue judged to be “highly 
contentious” had a comparable number of affirmation and negation 
statements or a rich variety of qualitative arguments pertaining to either 
                                                          
3 Subsequent mentions of “ethical issues” in the text should be taken to encompass 
ethical, social, and legal issues. 
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affirmations or negations. Typically, a highly contentious issue contained 
ethical debate about the underlying reasons for or against CE. An issue 
was categorized as “moderately contentious” if it was acknowledged as 
raising ethically significant questions but affirmations or negations 
occurred without substantial debate on the underlying reasons for or 
against the ethical issue. In this fashion, a moderately contentious issue 
indicated either a consensus issue among stakeholders or that the 
particular issue did not appear to raise a substantial ethical debate (Figure 
6.1 section 2A). 
 The second level of analysis consisted in building a model of the 
relationships between the ethical issues (Figure 6.1 section 2B). Parsing 
the arguments given for the affirmations and negations of the ethical 
issues revealed specific arguments that often had common underlying 
values  (personal effort, honesty, and equality), external factors (legal 
regulation, commercialization), or subsequent consequences (education, 
medicalization) of the non-medical use of MPH. The relationships were 
determined by looking for overlapping or related arguments to articulate a 
global understanding of how the ethics issues affected each other. 
Results 
Sixty-five individuals participated in one of nine homogeneous focus group 
discussions: 29 students (S) (mean age 20.9 years; focus groups A, B, C); 
21 parents (P) (mean age 53.8 years, focus groups D, F, H) and 15 
healthcare providers (HCP) (mean age 31.9 years, focus groups E, G, I). 
The groups varied in size from three to eleven participants. Each 
participant was assigned an alphanumeric code (e.g., A1) where the letter 
identified the stakeholder group they belonged to and the number 
indicated the order in which they were recruited. Results from the 
demographic questionnaire showed that the majority of participants were 
female (68%; N=44/65; S: N=22; P: N=12; HCP: N=10) and had obtained 
or were in the process of obtaining undergraduate or graduate degrees 
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(86%; N=57/65; S: N=29; P: N=15; HCP: N=13). None of the participants 
was currently using a prescription for MPH, but 3% had had a prescription 
in the past and 11% of the sample had previously used MPH for non-
medical purposes (Forlini and Racine In press). The commercial name of 
MPH, Ritalin, was used in the questionnaire because of its familiarity.   
We first present the content of the issues stakeholders viewed as 
contentious and non-contentious. Then, based on our focus group data, 
we propose a model to describe the relationship between the ethical 
issues identified. Stakeholders identified many ethical, social, and legal 
issues related to the non-medical use of MPH for CE. For all issues 
identified, stakeholders more often “affirmed” and discussed the existence 
of problematic ethical aspects of an issue than “negated” these aspects.  
We segregated the issues in relation to how contentious they were – 
highly, moderately or non-, contentious. None of the issues were deemed 
non-contentious or unproblematic. (See the methods section above for the 
classification method.) Table 6.1 and Figures 6.2-6.5 indicate whether 
arguments were made by students, parents, or HCPs, but no significant 
qualitative differences in the discussion of the ethical issues between 
these groups were observed. 
Moderately contentious issues: Commercialization, overprescription, 
illegality, and abuse 
Our analysis shows that commercialization, overprescription, illegality, and 
abuse were essentially moderately contentious issues; participants tended 
to agree on the existence of a problem without strong quantitative or 
qualitative differences between affirmation and negation statements. Table 
6.1 contains a summary of arguments made by participants on these 
moderately contentious issues and features some illustrative qualitative 
examples providing further context for each argument. No students 
expressed that potential commercialization of cognitive enhancers would 
be non-contentious, and participants across all groups agreed that the 
non-medical use of MPH was illegal.  
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Table 1.1: Qualitative examples illustrating stakeholders’ perspectives on moderately contentious issues around the non-
medical use of methylphenidate 
 
Issue Negation Affirmation 
Illegality 
Enhancement with MPH is likely illegal (S, P, 
HCP) 
 
“The way I see it is pretty straightforward. If it’s 
prescribed to you then you can use it if not it’s 
illegal (…).” (Student A6) 
 
“They are being sold on the black market so that 
in and of itself is illegal.” (Student D7) 
Regulation about the use of MPH for enhancement is unclear 
(HCP) 
 
“I hope it is illegal. But I never heard of any law that said you can’t 
take Ritalin if you don’t have the prescription.” (HCP E1) 
Abuse 
Enhancement can be a proper use of 
medication if occasional and does not disrupt 
daily life (S, P, HCP) 
 
“(…) we’ve applied substances that we already 
know about to solve new problems so maybe this 
is just another classic problem that has to be 
solved. Abuse is a dangerous term.” (Student A7) 
Enhancement is an improper use of medication (S, P, HCP) 
 
“I think it is abuse in this case, when you use the medication for 
another thing besides the purpose it is described.” (HCP E7) 
 
“Any drug can be abused and so, if it becomes obsessive then it 
becomes abuse.” (Student C6) 
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Commercialization 
Medications for enhancement may not be 
lucrative since they cannot be marketed (P, 
one HCP) 
 
“I am not sure that this would be such an 
enormous money maker for the pharmaceutical 
companies. Students don’t want to line up to a 
kiosk and take drugs on a regular basis. Nobody 
wants to live like that.” (Parent H3) 
 
There is a profitable market for medication used for 
enhancement (S, P, HCP) 
 
“If companies can put on market something that work even better 
than [Energy] pills and Redbull, then I am sure there would be a lot of 
people buying it.” (HCP G3) 
 
There are many conflicts of interests in the commercialization of 
medications (S, P, HCP) 
 
“you’ve got this whole pharmaceutical industry that’s living off of 
creating diseases.” (Student A9) 
 
“There is also the pressure of the pharmaceutical companies on the 
doctors. They just want the doctors to prescribe this now because the 
doctors and the companies will benefit from it.” (Student C7) 
Overprescription  
Overprescription is a misconception (one P, 
two HCP) 
 
“My girlfriend she is a teacher and she has 28 
kids in her classroom and only one child in her 
classroom in on Ritalin. Ritalin has not taken over 
the classroom. It has not.” (Parent H2) 
Medications used for enhancement, like MPH are readily 
available (S, P, HCP) 
 
“I think overprescription does have something to do with it because 
there are a bunch of people that are willing to sell their pills. So 
someone who gets it who really really really needs it for them self 
doesn’t have pills to spare.” (Student B2) 
*Neutral statements are not presented here given their marginal quantitative and qualitative salience. S: Students; P: Parents; HCP: Healthcare 
providers 
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Highly contentious issues: Authenticity of the individual, cheating, injustice 
and inequalities, and social meaning 
Authenticity, cheating, injustice and inequalities, and social meaning were 
highly contentious issues. Figures 6.2-6.5 show the contention about 
these issues in greater detail. In addition, discussion of two issues 
(authenticity and cheating) featured ambivalence. First, authenticity was 
discussed almost in equal proportion as a problematic (affirmation) and 
non-problematic (negation) issue. Authenticity was of interest across all 
stakeholder groups and produced arguments that were qualitatively 
oppositional (see Figure 6.2). In this case, the coexistence of conflicting 
perspectives on the issue of authenticity suggests that globally, 
ambivalence is the source of contention for this issue. We described this 
type of ambivalence as substantial ambivalence in contrast to 
informational ambivalence ( i.e., ambivalence caused by rather superficial 
misunderstandings, as has been discussed elsewhere (Forlini and Racine 
2011)). 
 Second, participants manifested ambivalence, but perhaps more 
accurately indecision, regarding the issue of cheating (Figure 6.3). This 
issue was discussed as mostly problematic, but we observed a high 
number of “neutral” statements. With the other issues we examined, 
neutral statements were marginal (quantitatively and qualitatively), but in 
the case of cheating, neutral statements were salient (quantitatively and 
qualitatively). In these open-ended neutral statements, participants neither 
affirmed nor negated that cheating was problematic, and this suggests that 
indecision is globally prevalent as opposed to the articulated statements of 
ambivalence for the issue of authenticity. The neutral statements on 
cheating also showed that participants found it difficult to determine if 
using MPH was cheating as compared to other substances and practices.  
 
 
 
 
 
 
 
 
 
NEGATION: An 
enhanced 
performance is 
authentic  
AFFIRMATION: An 
enhanced 
performance is 
inauthentic 
Figure 6.2: Qualitative examples illustrating stakeholders’ perspectives on the impact of non-medical use of MPH and the highly contentious 
issue of authenticity  
An individual that has used an enhancement still has to put in the effort 
to do their work (S, P, HCP) 
“…because even though it enhances your concentration and attention, the 
work, you’re still doing it. It’s not like if you get the exam and you get the 
answer in advance and you go to the actual exam and you copy the answer. 
… . But the actual work, you’re doing it just that you’re saving time in a very 
advanced way.” (Student A2). 
 
“Ritalin doesn’t seem to really enhance your intelligence and make you 
smarter it just kind of seems to be a different means of preparation that 
affects your organization skills” (Student B1). 
 “If this person took Ritalin and knows what he  
Is doing then so be it. The ultimate judge will  
beif you can or cannot do certain functions. It  
has to do with ability. Is that not it?” (Parent D5). 
 
The performance and effort are authentic but unfair (S, P) 
“Well, this girl from my high-school, she was a really good student and 
everything, but I found out that she took Ritalin before she took her SAT’s 
and she did do significantly better. … .The general opinion was that it was 
unfair but you could also say that she did put in a lot of work in general 
school for four years. That might have had more to do with it than her one 
SAT score.” (Student C4). 
Authenticity, in comparison, is not questioned in the medical context 
(S) 
“I mean, if you said taking Ritalin would make the work not yours then you 
would have to say anybody who had ADD or ADHD and who was on Ritalin 
didn’t do their work, nothing they did was theirs and I don’t think that’s right.” 
(Student B7). 
Enhancement may compromise the social and personal values that 
define identity and human nature (S, P, HCP) 
“… but eventually when you look at the person you lose your identity… 
You’ve done everything possible to make yourself the best in the world. So 
where is the person? What are we looking at? Something that science has 
created? Some clone of yourself?” (Student A8). 
“I think that we are losing the real value of a human being by being a 
machine or being too performance [oriented].” (Parent F2). 
An enhanced individual does not work as hard (S, P) 
   “I think I finally understand that line “It builds 
character”. I think it’s sad in a sense to lose that that  
[sic] character that you get out of working long  
hours by yourself and figuring out your study  
                                  skills. And if I look back on my life I’m at the  
academic point that I am today because I did it on  
my own and I worked those long hours and I didn’t  
use Ritalin and I think it’s sad that society  
doesn’t admire that as much today.” (Student B8). 
“You can keep taking it but you can’t fake that intelligence, fake that 
knowledge” (Student C5). 
An individual who has used an enhancement misses out on learning 
certain skills (HCP) 
“I am concerned as well for the lack of coping strategy that people are not 
developing through life. So their ability to cope with stress is really less 
because they always need that pill to cope with everything.” (HCP E2). 
“Drugs can’t teach us thinking. The university study must be about how to 
think. Now people don’t need to remember so much knowledge. Knowledge 
is everywhere, internet is easy access to everything.” (HCP I4). 
*Neutral statements are not presented here given their marginal quantitative and qualitative salience. S: Students; P: Parents; HCP: healthcare providers 
 
 
 
 
 
 
 
 
 
 
 
NEGATION:  An 
enhanced 
performance is honest 
and does not 
constitute cheating 
AFFIRMATION: An 
enhanced 
performance is 
dishonest and 
constitutes cheating 
Figure 6.1: Qualitative examples illustrating stakeholders’ perspectives on the impact of non-medical MPH use in the academic context on 
the highly contentious issue of cheating 
Enhancing performance is unfair because it is dishonest and a shortcut in 
learning (related to authenticity) (S, P, HCP) 
“It’s basically like a replacement for doing work in certain instances, but it is a 
poor replacement.” (Student C8) 
“I find that a lot of students who end up taking Ritalin in the arts program is 
because they never went to class. … people who actually work and have that 
work ethic in them are not going to want to take the drug, they don’t need to.” 
(Student C2). 
“If I took it and went to the exam and did well on that exam, I would have the 
biggest guilt complex. … . I would think that it was all the drug.” (Student C5). 
 
                                             “And the easy button to press for something 
                            without longer work for it.” (HCP I4) 
 
         Enhancing performance puts others  
                                    at a disadvantage (S, P, HCP) 
 
           “Although when I was at university and I 
encountered it for the first time I was shocked. I was surprised at how 
prevalent it was. It certainly made me feel as though I was at a disadvantage 
because I wouldn’t have taken the Ritalin to enhance my performance (…).” 
(HCP I3) 
 
Enhancing performance is against the rules/law (S, P) 
      “It is if it’s against the law. You weren’t supposed to, you did it, it’s cheating.”   
(Parent D6) 
Enhancing performance with a cognitive enhancer can be 
considered a study tool like any other (S, P, HCP) 
“I don’t know, it doesn’t sound like cheating. If you take a cup of coffee 
or a Red Bull like they say, nobody is going to say you were cheating.” 
(Student C1)  
“It is hard for me because I can’t say that it is cheating because you are 
under pressure and you need to perform.” (HCP E2)  
 
“They still teach these things that people would maybe argue are aids to 
cheating but with Ritalin because you can’t see it on  
the surface, that’s where it becomes controversial.“ 
(Student B10). 
 
An individual who has used an  
enhancemenstill does the work (related to  
authenticity) (S, P) 
 
“Cheating means more like copying the work from the  
other person, this way you are still doing the studying, it is just that you 
have enhanced powers, if you want to call it that ….” (Parent F1) 
 
There are no rules to say that an individual cannot enhance their 
performance (P) 
 
“I think that there is no standardization. There is no academic law that 
says you can’t use this. Then you are not cheating.” (Parent H3) 
NEUTRAL: It is unclear whether an enhanced performance is honest and constitutes cheating or not 
“I have known so many people [in university] who have had panic attacks and stuff…It just seems impossible and how much pressure is put on these 
students…And if you know there’s an easy way to just help you pass because you’ve just got to pass that class to graduate, well, you know…” (Student 
A10) 
“… no one’s going to tell you not to have a cup of coffee before and exam or no one’s going to tell you not to buy a special program to put on your laptop 
that makes referencing the sources on your paper easier. No one’s going to tell you not to help yourself other ways just that it’s in a pill form and that’s 
what sort of gets everyone… It’s a drug but so is coffee” (Student B4). 
S: Students; P: Parents; HCP: healthcare providers 
 
 
 
 
 
 
 
 
 
 
 
NEGATION: Access to 
MPH does not impact 
the fairness of an 
enhanced performance   
AFFIRMATION: Access 
to MPH impacts the 
fairness of an enhanced 
performance 
Figure 6.2: Qualitative examples illustrating stakeholders’ perspectives on the impact of non-medical MPH use in the academic context on 
the highly contentious issue of justice* 
 
Individuals who seek it will find it (S, P, HCP) 
“I think in terms of fair access if you want it bad enough you will find a 
way to get it, period. Illegally, legally, whatever it might be, (…).” 
(Student B10) 
Injustice is innate in society (S, P) 
“I feel like we can minimize it but you can never ever get rid of that. 
And on another note that you guys were talking about putting people 
at the same level theoretically that’s impossible  
because there are always people who have just  
natural abilities and are better than others and  
you can obviously never get rid of that but  
you can get rid of the part where those abilities 
are drug-enhanced.” (Student A6)  
 
“(…) what if we even the playing field and make everything available 
for everyone: steroids, Ritalin, plastic surgery and everyone looks 
great and can concentrate for 20 hours and has muscle mass like 
Barry Bonds are you even really leveling the playing field then 
because it’s about character and values and not about you know 
whether you have the muscle to do it or the drugs make you better? 
… if you make it available the choice to take the drug is up to the 
person and if it’s available to everyone and everyone does take it 
there’s still going to be someone who stands out in all that and it’s not 
the drug that did that.” (Student A1) 
Enhancement can cause unfairness and cause individuals to feel 
they are at a disadvantage (S, P, HCP) 
“If you are saying that Ritalin enhances performance then there is 
obviously an unfair advantage for the students who are taking the drug 
vs. those who don’t have access. “ (Parent D7) 
Resources are being diverted from patients in terms of medication 
and medical attention (S, HCP) 
“People are going to doctors wasting their time 
trying to find the one doctor that is going to give them  
a prescription for Ritalin or however they get  
these pills and this is public money that is  
wasted. And whenever you waste a dollar  
of public money that takes a dollar away from 
somebody who needs it more: somebody who 
 was just hit by a car or whatever chronic illness 
they have.” (Student A5) 
Cost of medications used for enhancement can be a limiting factor 
for individuals  (P) 
“I have no idea but what is the cost of Ritalin? Is it expensive, is it 
cheap? They say that it is obtained on the black market. I am wondering 
what happens in a class where you have students that can’t afford the 
cost of this drug.” (Parent D7) 
 
*Neutral statements are not presented here given their marginal quantitative and qualitative salience. S: Students; P: Parents; HCP: healthcare providers 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NEGATION: 
Enhancement of 
academic performance 
with MPH is not bringing 
about changes in society 
AFFIRMATION:  
Enhancement of academic 
performance with MPH is 
bringing about changes in 
society 
Figure 6.3: Qualitative examples illustrating stakeholders’ perspectives on the impact of non-medical MPH use in the academic context on 
the highly contentious issue of social meaning* 
The changes in education are a 
part of a natural progression of 
assimilating new technology  
(S, P) 
“Like all the advances that we 
have and like technology and 
medicine and like literature and a 
lot of it and stuff is because people 
have time to do other things 
because we have technology 
because people don’t have to 
spend  
hours looking  
in a  
dictionary  
because  
we have  
spellcheck  
so you know (…) .”  
(Student B7) 
Society is already performance-
based (P, HCP) 
“It is already performance based, 
school right now is performance 
based. If you want to do a 
master’s or a doctoral degree well 
you have to have the best grade. 
(…) it is already based on 
performance. I am not sure that 
Ritalin is going to change that 
because it is already like that.” 
 (HCP E1) 
 
Enhancement is bringing about changes in the goals of education (S, P, HCP) 
“I think that it has taken education and made it equivalent to performance. (…) you take a course, you go to 
university, or you finish a class and six weeks later you don’t know what you have learned. You don’t have to know 
what you have learned because the whole point was to pick up that information, regurgitate that information on a 
test, spit it out on the essay, put it in the final (…).” (HCP I3) 
Enhancement may have an effect upon professional life beyond school (S, P) 
“When they will graduate they will go on the market and they will keep on having trouble and they will have learned 
to solve their problems with the drug so I think that is a social problem that these students that are abusing don’t 
learn.” (Student A2) 
“I think it’s an interesting thought to wonder if maybe you can enhance the performance of certain professionals 
maybe like I guess a brain surgeon. … . Like if you’re more alert and focus better like 
maybe it’ll help your purpose.” (Student B1) 
            Social emphasis on performance (S, P, HCP) 
     “I am concerned about the tolerance that, not the tolerance but if we get used to  
the feeling of being on Ritalin, (…) . I wonder how they are going to conceptualize  
human performance, just the normal human performance. (…) . I am afraid that there  
is going to be a new norm of performance … .”  (HCP E2) 
Using medication for enhancement medicalizes performance and acts as a “quick fix” for problems that are 
not necessarily biological (S, P, HCP) 
“For many many of our common, everyday problems we have: the solution resides in the pill.” (Student A5) 
Changes caused by availability of prescription medications for such uses (S, P, HCP) 
“It just hit me right now maybe this whole situation with Ritalin is the canary in the coal mine. Shouldn’t we be 
worried about how readily accessible pharmaceutical drugs are to the population? … . Obviously this system isn’t 
working that well if we’re having a whole conversation today on how easily accessible a prescription drugs is to 
students to take for a non-prescription purpose.” (Student A5) 
Concern for the public health messages that are being sent through enhancement practices (S, one P) 
“I would have a problem with society sending the message that you need this drug to do your best. And that’s 
ultimately the message that’s being sent if you make it open, available like candy jars full of Ritalin.” (Student B8) 
*Neutral statements are not presented here given their marginal quantitative and qualitative salience. S: Students; P: Parents; HCP: healthcare providers 
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Identifying a model describing the relationships between ethical, social 
and legal issues  
In discussing the ethical, social, and legal issues related to the non-
medical use of MPH for CE, participants in our focus groups expressed 
that these issues were inextricably linked to certain values, external 
factors, and subsequent consequences. Specific values contributed to 
positioning issues as problematic or not. Figure 6.6 captures the 
relationships between issues and specific values. In conjunction with 
Figures 6.2-6.5, this model demonstrates how the highly contentious 
issues (authenticity, cheating, justice, and social meaning) represent 
values that affect individual and social decisions, while the moderately 
issues seemed to act more as external factors (legislation, markets, 
medicine) that affected these decisions. We further describe the 
relationships schematized in Figure 6.6, and readers should use the figure 
as a guide to the following explanations on the four relationships described 
in the model.   
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Effort-authenticity relationship (R1): Effort is linked to the underlying belief that work put into an activity contributes to shaping personal identity and being an authentic 
individual. 
Honesty-equality of opportunity relationship with fairness (R2): Fairness is defined by the values of honesty and equality of opportunity responds to social and interpersonal 
aspects of CE (i.e. the effects of an individual’s behaviour on that of others).  
External factors relationship (R3):  The regulation derived from legislation and medical practice that dictate what constitutes a proper use of a medication and the channels 
through which performance enhancers are accessed are two key factors that shape the values of honesty and equality of opportunity. These factors are different from the 
values discussed earlier because they rely more heavily on norms established by government, professional societies, and the pharmacological industry.  
Society-performance relationship (R4): The complex ethical landscape of the non-medical use of prescription medication for performance enhancement is causing problematic 
social changes and creating an overarching concern for the altered meanings of performance and achievement as well as the role of medicine (medicalization) and education. 
Value of EFFORT 
(authenticity) 
 
 
Value of EQUALITY OF 
OPPORTUNITY (justice) 
Value of HONESTY 
(cheating) 
 
External factor of REGULATION  
(illegality & abuse) 
 
External factor of ACCESS 
(commercialization & 
overprescription) 
Subsequent consequences of changes in  
MEDICALIZATION 
EDUCATION  
(social meaning) 
R1 
R2 
R3 
R4 
Figure 6.4: Model of ethical, social, and legal issues and the underlying values identified by stakeholders that cause these issues to be 
contentious 
 
R3 
FAIRNESS 
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Effort-authenticity relationship (R1): Effort is a constitutive element of an authentic 
academic performance 
University students, parents, and healthcare professionals largely defined 
authenticity in terms of the effort that an individual has to exert in order to achieve 
and succeed. Effort is linked to the underlying belief that work put into an activity 
contributes to shaping personal identity and character (Figure 6.2). Consequently, 
when prescription medications are used as cognitive enhancers, the effort-
authenticity relationship is jeopardized and perhaps discounted. A discounted effort, 
in turn, potentially results in an individual who betrays his or her current personal 
values and beliefs. It also affects the “future” individual who has not gained the 
experience of effort he or she would have had without the enhancer. The difficulty, 
however, remains in how to measure the effort and its distinctive contribution to the 
authenticity of a performance.  In the words of HCP I3:  
[Y]ou have individuals that, you know, definitely start out with a 
deficit and Ritalin let’s say brings them up to average. Then you 
have individuals who are starting out as average and it brings 
them up above average. Then you have individuals who are 
above average and it brings them up to another level. So, I 
mean, it is such a sliding scale in terms of, is it still your 
performance?  
 
The effort-authenticity relationship we have outlined in our analysis largely relies on 
the assumption that ethical judgement is an individual and internal norm. It also 
assumes that an individual would be conflicted in the choice to take an enhancer or 
not and that effort is the only way to develop or change one’s identity authentically. 
Honesty-equality of opportunity relationship with fairness (R2): Honesty and equality 
of opportunity confer two distinct meanings to fairness  
Fairness was identified by stakeholders in our focus groups as a major issue. 
Analysis of the use of “fairness” showed that it referred to two values: honesty and 
equality of opportunity. On the one hand, fairness was defined by the value of 
honesty and the issue of whether using MPH to enhance academic performance 
constitutes cheating. On the other hand, fairness was defined in terms of equality of 
opportunity to obtain MPH (or other such cognitive enhancers) and opportunities 
deriving from its use.  
Fairness as defined by the values of honesty and equality of opportunity 
responds to social and interpersonal aspects of CE, that is, the effects of an 
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individual’s behaviour on that of others. For example, questions of fairness arose 
when the performance of an individual using a prescription medication was 
compared to an individual who did not in terms of (1) the perceived effort required 
and (2) whether both parties had the opportunity to access the prescription 
medication. The comparison of the outcomes of individuals who engage and abstain 
from using prescription drugs to enhance cognitive performance is what, in this case, 
seems to render what has been considered a personal choice ethically problematic. 
Those who enhanced their performance and succeeded were perceived by a group 
of participants to (1) not have put valuable effort into their performance and (2) 
gained an advantage because of an opportunity that was not available to all.  
External factors relationship (R3): External factors affect individual and collective 
ethical opinions and behaviours 
Another component in the model of interaction between issues and underlying 
values are the external factors that participants identified as influencing the ethics of 
the non-medical use of prescription drugs for CE. Participants identified two key 
factors: (1) regulation derived from legislation and medical practices that dictate what 
constitutes a proper use of a medication and (2) the channels through which 
performance enhancers are accessed. These factors are different from the values 
discussed earlier because they are norms or practices established by government, 
professional societies, and the pharmacological industry. In the first case, regulation 
had a substantial impact on what was perceived as fair. For example, some 
stakeholders questioned whether their perspectives about fairness might be different 
if the regulations were clearer.  As one student commented,  
“[m]y gut instinct is to say it is cheating, that is what I would 
go for first and foremost. The question I would have for 
everyone is if these pills were legal and available would it be 
ethical to take it? Is it the illegality that makes it seem 
unethical to us? Is it the availability, is that all?” (Student C9)  
 
The other external factor, access, illustrates that stakeholders expect that the 
pharmaceutical industry and the prescription practices of some physicians could be 
causing an increase in access to drugs like MPH, which, in turn, increases the 
prevalence of the non-medical use and results in further social consequences.  
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Society-performance relationship (R4): A subsequent consequence of broad social 
use of cognitive enhancement is a change in the meaning of performance and 
achievement 
Our data pointed to many ways that participants believed that the non-medical use of 
prescription medication for CE was both bringing forth and resulting from broad 
social change. Stakeholders described CE as a problematic social change and 
expressed an overarching concern for how the non-medical use of prescription 
medication for performance enhancement changed what it means to perform well 
and achieve. There were concerns that the non-medical use of prescription 
medications encouraged the medicalization of performance and ultimately, 
medicalization of health more generally. In contrast, it was also suggested in the 
focus groups that health concerns should actually be focused on mental health more 
broadly and not on the pressure to perform using cognitive enhancers. In the words 
of a student participant discussing the use of Prozac for enhancement purposes: “I 
haven’t seen a focus group about students who are depressed, which I think might 
be an even bigger problem because with depression you can’t even get out of bed 
and do your work” (Student C2). Furthermore, according to participants, the 
importance of authenticity seemed to impact how society approaches education and 
training for the workforce. 
Discussion 
In this study we identified ethical, social, and legal issues (e.g., authenticity, 
cheating) related to the non-medical use of MPH for CE from the point of view of 
university students, parents, and healthcare providers. In addition to identifying and 
describing these issues in depth using a qualitative methodology, we closely 
examined supporting arguments from these stakeholders. These arguments 
informed the positions taken by stakeholders to affirm or negate that these were 
ethical issues (Figures 6.2-6.5). Our results suggest that the ethical issues we 
identified in the focus group discussions with stakeholders were similar to those 
identified in a previous discourse analysis of the bioethics literature (Forlini and 
Racine 2009b). This previous analysis showed that stakeholders had divergent 
perspectives about the acceptability of CE as a practice based on conceptions of 
autonomy of the individual; however, they recognized the potential constraints of 
personal choice based on social pressures for performance (Forlini and Racine 
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2009a). These findings framed the way in which stakeholders value personal 
integrity (authenticity) for the individual and his or her performance but also 
acknowledged that there are social causes and consequences to CE.  
However, in this paper, closer observation of the nature and proportion of 
arguments in stakeholder perspectives on a broad range of ethical issues allowed us 
to deepen our understanding of the perspectives on authenticity, social meaning, 
and other issues, while observing the existence of two levels of contention as well as 
factors and values underlying the issues identified (Figure 6.6). In the following 
section, we explore the underpinnings of different levels of contention, highlighting 
the important role that the concept of self-identity plays in stakeholder perspectives 
alongside the values of authenticity, honesty, and equality of opportunity. We then 
explore how such concepts and values are or could be captured in policies about 
CE. 
 The limitations of our focus group study have been discussed in previous 
publications of other data (Forlini and Racine 2009a; Forlini and Racine In press). 
This paper presents distinct data and incorporates an added level of analysis for 
identifying moderately and highly contentious issues. As a result, the model of 
interaction depicted in Figure 6.6 may be considered as a model for use in 
hypothesis generation as opposed to hypothesis testing.  
Understanding the underpinnings of the different levels of contention in stakeholder 
perspectives on the ethics of CE and the central role of authenticity 
In our study, moderately contentious issues (i.e., commercialization, 
overprescription, illegality and abuse) were typically issues where there was 
consensus among stakeholders about whether a substantial ethical problem existed. 
For example, participants agreed that access to prescription drugs used as cognitive 
enhancers is ethically problematic because it is currently facilitated (in their view) by 
overprescription by physicians and increases the potential for further 
commercialization of these drugs. At a deeper level, we observed that moderately 
contentious issues were tightly coupled with external factors (Table 6.1 and Figure 
6.6). For example, issues such as overprescription and commercialization showed 
how the external factor of access to medications can jeopardize the value of equality 
of opportunity. Likewise, the issues of illegality and abuse were associated with the 
external factor of regulation that influences what is considered honest. In this 
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fashion, the moderately contentious issues and the factors they are identified with 
seem to exert an external influence on the ethics of CE that may make stakeholders 
feel like CE is highly prevalent in their environments. 
 In contrast to moderately contentious issues, highly contentious issues (i.e., 
authenticity of the individual, cheating, injustice and inequalities, and social meaning) 
prominently featured ethical debate about the effects of non-medical use of MPH and 
how these effects might shape the arguments for or against their use. On these 
issues, stakeholders debated intensely between competing arguments. An example 
of this type of debate is whether CE can be considered cheating.  On the one hand, 
a cognitive enhancer could be comparable to another study tool and which still 
requires the individual to do the work themselves. On the other hand, CE could be 
dishonest, constitute a short-cut in learning, and put others at disadvantage (Figure 
6.3).  
As indicated in our methodology, the designation of “highly contentious” 
hinges more on the existence of a rich variety of qualitative arguments pertaining to 
either affirmations or negations and not necessarily a strong quantitative 
disproportion between the two types of statements. Contentious issues like cheating 
and social meaning raised questions revolving around the perhaps more intrinsic 
questions of “Who are you?” and “Who do you want to be?” The answers to these 
questions can draw upon both individual and socio-cultural preferences. These 
questions address the prominent concern that stakeholders in our study had for the 
effect of the substances used for CE on their academic performance and ultimately 
their self-identity and authenticity.  
We suspect that the link with the personal concept of self-identity and 
authenticity could partly explain what distinguishes or even causes an issue to be 
highly contentious. Our own study, because of its design and limitations, falls short of 
answering this question. However, other stakeholder studies have specifically 
examined the issues of authenticity, fairness, and autonomy and provide support for 
this hypothesis, which helps to explain different perspectives and understanding of 
these issues among stakeholders.  The concern for authenticity has been shown to 
impact stakeholder willingness to use and ban enhancers and has important 
interactions with other values (Sabini and Monterosso 2005; Riis, Simmons and 
Goodwin 2008). Enhancement of mood, emotions, and memory are seen to have 
more of an impact on self-identity than enhancement of attention and concentration, 
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just as enhancement by prescription medications were thought to have more of an 
impact than natural means (e.g., natural products and mental training exercises 
(Sabini and Monterosso 2005; Bergstrom and Lynoe 2008; Riis, Simmons and 
Goodwin 2008)).  In scholarly writings, the value of effort which contributes to 
authenticity also has great importance, and it binds opposing opinions on the 
broader ethical landscape of CE (Parens 2005). Both proponents and critics of CE 
agree that self-identity should be preserved but diverge in their perceptions of 
whether it is damaged by an intervention that enhances any aspect of cognition. 
An issue like authenticity could become even more important and complex 
when it is put into a social context to consider equality of opportunity. Our qualitative 
analysis (Figure 6.6) suggests that fairness was defined by a relationship between 
effort and honesty, as values, with the value of equality of. In other words, a complex 
combination of internal and external influences appears to shape perspectives on 
fairness.  Our own data does not allow us to go further than generating this 
hypothesis, but a survey study by Sabini and Monterosso provides additional 
perspectives. They asked undergraduate students at the University of Pennsylvania 
to rate the fairness of certain academic situations involving performance 
enhancement with medications. The majority of students that participated in that 
study thought that using a substance was fair if it acted as a normalizer to help the 
bottom 10% of the population as opposed to an enhancer that helped normal or high 
functioning individuals (Sabini and Monterosso 2005). In this respect, students felt 
that it was fair to help underperforming individuals gain access to opportunities that 
normal or high performing individuals can access.   
The concept of a normalizer can be taken one step further in that a cognitive 
enhancer can also be considered an “enabler of one’s true self” (Riis, Simmons and 
Goodwin 2008, p. 505) to realize one’s full potential as a way to gain fair access to 
desired opportunities and achieve goals. This argument about the acceptability of 
normalizers as opposed to enhancers has also been voiced in the bioethics literature 
(Sandel 2004; Levy 2007). However, the choice to use a cognitive enhancer has 
been described by stakeholders and popular works of fiction as influenced by 
pressures to compete and succeed in society; external factors are therefore 
important considerations in the choice to enhance or not (Forlini and Racine 2009a; 
McKenna 2011). In this fashion, the authenticity-related question of “Who do you 
want to be?” is in part dictated by the pressure exerted by these external factors 
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(e.g., “What does society want me to be?” and “Who do I need to be to perform, 
succeed and to some extent comply with social expectations?”).   
The stakeholder perspectives we gathered suggest that CE challenges certain 
fundamental values held by individuals as well as society. We argue, based on our 
own data and that of others, that a high level of contention surrounding issues in CE 
may be explained, at least in part, by the important value of effort and the related 
value of authenticity. However, an issue such as fairness likely introduces interplay 
between both the internal and external factors reflected in our data. Our discussion 
points to a perhaps unsuspected complexity, when compared to academic debates, 
in understanding the relationship between different values and issues brought forth 
in the CE debate as well as an important role of certain core values in opinions about 
CE. The next section examines current policies on CE and whether it is at all 
possible to capture the current complexity of stakeholders’ perspectives about CE in 
them.  
Shaping policy with stakeholder perspectives? 
The important academic debate surrounding CE, coupled with substantial media 
coverage of prevalence studies and opinions about the efficacy of medications used 
for CE, have led different professional and regulatory bodies to further examine 
policy and regulatory aspects of CE for clinicians and society at large.  For example, 
the British Medical Association surveyed some of the ethical issues associated with  
CE and developed a discussion paper on CE, although the goal of the paper was 
perhaps less intended to guide clinicians than to contribute to fostering public 
discussion on CE. The report of the Commission de l’éthique de la science et de la 
technologie from Québec, Canada (Commission de l’éthique de la science et de la 
technologie 2009) issued a report that was developed as a contribution to public 
debate but also offered specific recommendations for governmental authorities and 
clinicians. The report recommended increasing education for clinicians about CE and 
ensuring monitoring of the current public health situation (Outram and Racine 2011). 
Perhaps the most concrete and directive guidelines were proposed by the American 
Academy of Neurology (AAN), which was created specifically to inform and guide 
neurologists in their practice in response to requests from adult patients for cognitive 
enhancers (Larriviere et al. 2009). But even the AAN left ample room for individual 
31 
 
clinicians to determine their own positions and understanding of the ethical 
acceptability of CE by stating that “prescription of medications for 
neuroenhancement occurs within the physician-patient relationship” and that CE is 
neither legally nor ethical obligatory in addition to being legally and ethically 
permissible (Larriviere et al. 2009, p. 1408). Given its more concrete and specific 
focus, the attempt of the AAN to counsel clinicians is perhaps the best starting point 
to examine if and how concerns of stakeholders are and can be taken into 
consideration in policies.  
The guidelines published by the AAN about CE were innovative and among 
the first to advise a group, in this case medical professionals, on how they might 
approach requests for neuroenhancement. In the end, the AAN’s position was 
largely non-directive, putting the onus on individual neurologists to evaluate the 
request of the patient, much in the style of a request for medical treatment.  From 
this perspective, these guidelines adopted a moral acceptability approach by 
examining CE, “within an existing framework while respecting social and legal 
obligations” (Racine 2010, p. 124). A moral acceptability approach captures extrinsic 
sources of morality such as the law, social consensus, and socially accepted norms. 
This stance brings forth questions of what clinicians can do instead of whether or 
why they should be involved.  
In seeking to map out what is permissible, guidelines and policies like the one 
proposed by the AAN do not clearly capture the full complexity of substantial values 
and concerns like those brought forth by the CE debate and discussed by 
stakeholders (and in this case patients). For example, we found that effort and 
authenticity as well as self-identity are very important considerations for 
stakeholders. The salience of these issues intersects with the existence of an 
important body of theoretical and philosophical literature on CE on the topic of 
authenticity and self-identity (Parens 2005; Bolt and Schermer 2009; Bublitz and 
Merkel 2009). Some of the more intrinsic sources of morality (of both clinicians and 
patients) may have been skimmed over in the AAN guidelines. Intrinsic sources of 
morality (e.g., empathy and self-reflection) are key in determining moral 
praiseworthiness and deciding, “if we should morally and ideally pursue cognitive 
enhancement” (Racine 2010, p. 125). In contrast, the AAN guidance is rather 
procedural and leaves different options open, doing little to arrive at the crux of what 
may cause moral unrest for clinicians and patients.  
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Our analysis should not be read as direct criticism of the AAN’s guidelines as 
such but rather as pointing out that guidance by professional bodies like the AAN 
can only be a partial response to a problem which calls for a more comprehensive 
and global approach. We wish to highlight the difference between what the 
guidelines set out to do and the type of reflection we observed among our 
participants. This difference brings us to recognize a potential limitation in the reach 
of debates held within specific contexts, such as the medical context of the AAN. 
Perhaps the AAN guidelines or the physician-patient relationship are simply not the 
venue to discuss values like effort and self-identity. However, in spite of this 
limitation, we should not understate the importance of opening up clinical 
conversations to different attitudes and opinions about CE as proposed by the AAN 
in its guidelines. This is considerable progress in contrast to a more paternalistic or 
authoritative stance that would state for patients and clinicians what is the best 
ethical decision to make, or even worse, simply dismiss the topic of CE.  
At the same time, one can only be partially satisfied by the procedural nature 
of such guidance given the stakes at hand. Examining the moral acceptability of CE 
as the AAN has done is an initial way to determine the morality of CE. However, it is 
but a partial answer to the CE problem and its complex nature.  We have ourselves 
commented that this guidance seemingly lacked awareness of the broader ethical 
and social issues surrounding such requests (Racine and Forlini 2010) despite the 
guidelines’ authors maintaining that these factors were considered during the 
genesis of this publication (Larriviere and Williams 2010). Indeed, issues like 
autonomy and justice were mentioned in the guidelines but lacked the type of 
consideration that would have been informed by a second moral parameter looking 
at moral praiseworthiness by incorporating some reflection on contentious values or 
even the external factors which indirectly relate to the type of socio-economic 
environment in which CE is developing (Racine 2010).  
Consider, for a moment, how the AAN guidance may have changed if some of 
the values outlined in Figure 6.6 that are pertinent to the medical context were part of 
the recommendations. Neurologists are encouraged by the AAN to rule out any 
underlying medical condition in a suspected request for cognitive enhancers. Once 
this is done, the physician-patient conversation exits the realm of the core traditional 
goals of medicine, bringing in a host of other questions of a more social nature to 
determine whether CE is appropriate not only for the patient but perhaps also for the 
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profession and society. In the case of patients, such a request may be motivated by 
social pressures to perform in academic or professional environments (Teter et al. 
2005; Rabiner et al. 2008; Forlini and Racine 2009a). According to the AAN, 
physicians, as the gatekeepers for medications, are not ethically obliged to prescribe 
or withhold cognitive enhancers for CE and thus must also reflect upon how to deal 
with requests motivated by social pressures within their practice. These questions go 
beyond what is presented in the AAN’s discussion of patient autonomy and the 
clinician’s responsibility to protect the patient from the potential harms of CE related 
to the medications, of which the side-effects are unclear.  
As found in our study, a related contentious issue of importance to 
stakeholders is that of medicalization. The AAN defines “neuroenhancement” as 
“prescribing medications to normal adult patients for the purpose of augmenting their 
normal cognitive or affective function” (Larriviere et al. 2009). However, what is 
missing from this definition is a discussion of how the definition of health has 
changed and may continue to change over time. The committee might have taken 
the opportunity to clarify their position on the treatment-enhancement distinction and 
the goals of medical practice within neurology.  
The strict discussion within the context of neurology brings yet another 
contentious issue to the surface, that of justice and the value of equality of 
opportunity. The AAN guidance recognizes that CE may fall into the “lifestyle drug” 
category that is available to those who can afford it. However, even before that, 
access to the neurologists who prescribe these drugs could be limited in certain 
healthcare contexts. These are but a few possibilities that illustrate how the values 
articulated by participants in our study might lead to policies that are not 
circumscribed by what is acceptable in existing legal and ethical frameworks.  
More open-ended and societal efforts could help develop creative ethical 
approaches to CE. The goal would be to not only ensure a form of moral 
acceptability (like the AAN guidance) but to also capture deeper questions about the 
moral praiseworthiness of CE to bring both extrinsic and intrinsic sources of morality 
into the debate (Racine 2010).  Recent empirical research about the values held by 
stakeholders in their reflection on the ethics of CE could inform such thinking.  
Dewey’s concept of social intelligence, or democracy, is an apt concept to 
capture how stakeholder values are important to consider in ethical debates such as 
the one around CE. The ways in which individuals will arrive at these actions, Dewey 
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proposes, is through deliberation which is, “an experiment in making various 
combinations of selected elements of habits and impulses, to see what the resultant 
action would be like if it were entered upon” (Dewey 1922, p.190). In this sense, 
deliberation requires that issues be considered as a function of the different values of 
those involved, an endeavour more akin to seeking moral praiseworthiness than 
moral acceptability or “what is expedient, politic, prudent, measured by 
consequences” (Dewey 1922, p. 189). 
The data we collected through focus groups is evidence that stakeholders are 
still engaging in deliberation about the ethics of CE and are far from making a choice 
about whether CE will become a custom. However, the concerns and values of the 
stakeholders do not come through if one relies only on professional groups for 
guidance regarding CE. Perhaps what is needed is a subsequent collaboration of 
professional associations with the humanities for a joint deliberation such that moral 
acceptability and praiseworthiness are examined jointly from both points of view. 
Bioethics is an appropriate venue to bring these perspectives and disciplines 
together. 
Conclusion  
Our findings bring to light contentious issues in the ethics debate around CE and 
their underpinnings from the point of view of stakeholders. Issues that were 
moderately contentious were found to be associated with external factors while these 
external factors shaped perspectives on the set of highly contentious issues. Highly 
contentious issues were accompanied by divergences in fundamental values such 
as effort, honesty, and equality of opportunity that stakeholders thought had a 
broader impact on health and education. The collision of these values and external 
factors in the deliberation of stakeholders brings a new dimension to the CE ethics 
debate that calls for reconsidering the directions of the debate in academia and 
policy. These discourses have been limited to mainly examining the moral 
acceptability of CE yet have been interpreted as a global response to a question that 
research has shown to be much broader and deeper than “can we or can’t we?” One 
such new direction is to turn the gaze of current ethics discourses toward the moral 
praiseworthiness of CE that would pay closer attention to different sources of 
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morality and the values that accompany them when determining the possibilities for 
the best ethical approach to CE.      
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